- Home
- CDIO vs XXII Comparison
CDIO vs XXII Comparison
Compare CDIO & XXII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDIO
- XXII
- Stock Information
- Founded
- CDIO 2017
- XXII 1998
- Country
- CDIO United States
- XXII United States
- Employees
- CDIO N/A
- XXII N/A
- Industry
- CDIO Biotechnology: Commercial Physical & Biological Resarch
- XXII Medicinal Chemicals and Botanical Products
- Sector
- CDIO Health Care
- XXII Health Care
- Exchange
- CDIO Nasdaq
- XXII Nasdaq
- Market Cap
- CDIO 6.8M
- XXII 6.2M
- IPO Year
- CDIO N/A
- XXII N/A
- Fundamental
- Price
- CDIO $3.71
- XXII $1.24
- Analyst Decision
- CDIO
- XXII
- Analyst Count
- CDIO 0
- XXII 0
- Target Price
- CDIO N/A
- XXII N/A
- AVG Volume (30 Days)
- CDIO 35.2K
- XXII 1.3M
- Earning Date
- CDIO 11-14-2025
- XXII 11-04-2025
- Dividend Yield
- CDIO N/A
- XXII N/A
- EPS Growth
- CDIO N/A
- XXII N/A
- EPS
- CDIO N/A
- XXII N/A
- Revenue
- CDIO $19,507.00
- XXII $18,071,000.00
- Revenue This Year
- CDIO $1,434.82
- XXII N/A
- Revenue Next Year
- CDIO $4,661.91
- XXII $126.57
- P/E Ratio
- CDIO N/A
- XXII N/A
- Revenue Growth
- CDIO N/A
- XXII N/A
- 52 Week Low
- CDIO $3.22
- XXII $1.19
- 52 Week High
- CDIO $53.10
- XXII $341.55
- Technical
- Relative Strength Index (RSI)
- CDIO 44.85
- XXII 36.61
- Support Level
- CDIO $3.58
- XXII $1.19
- Resistance Level
- CDIO $3.99
- XXII $1.35
- Average True Range (ATR)
- CDIO 0.30
- XXII 0.12
- MACD
- CDIO -0.04
- XXII -0.02
- Stochastic Oscillator
- CDIO 24.48
- XXII 6.54
About CDIO Cardio Diagnostics Holdings Inc. Common stock
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.
About XXII 22nd Century Group Inc.
22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.